Dossier assessment

Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-74
Last updated

Report documents

  1. Extract of dossier assessment

    Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 598 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-74_en
  2. Dossier assessment

    Guselkumab (ulcerative colitis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 879 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-74

Dossier assessment

Indication:

Adults with moderately to severely active ulcerative colitis

Result of dossier assessment:
  • Patients who have had an inadequate response with, lost response to, or were intolerant to conventional therapy: added benefit not proven
  • Patients who have had an inadequate response with, lost response to, or were intolerant to a biologic agent (TNFα antagonist or integrin inhibitor or interleukin inhibitor): added benefit not proven

Press releases

Ulcerative colitis: Comparative study provides important insights

The data reveal no added benefit of guselkumab over golimumab.

Additional information

Federal Joint Committee (G-BA)

2025-11-20 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A25-74
Commission
Commission awarded on 03.06.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-74_en

Connected Projects

  1. Dossier assessment

    Guselkumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-112
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-60
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Guselkumab (Crohn’s disease) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-75
    Last updated

    Status: Commission completed

  4. Addendum

    Guselkumab (ulcerative colitis) – Addendum to Project A25-74

    Project no.
    A25-132
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Guselkumab (plaque psoriasis in children and adolescents) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-163
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form